Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.
Keiichi Fujiwara, MD, PhD
Advertisement
Articles by Keiichi Fujiwara, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
4
Dr Neff on the Accuracy and Feasibility of Self-Collected HPV Testing in Cervical Cancer
5